ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/SMO-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/SMO-inhibitor
6
trial(s) found.
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
anti-ERBB3 antibody-drug conjugate
+ SMO inhibitor
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
+ SMO inhibitor
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
+ SMO inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05384626
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1) (
NVL-655-01
)
ALK inhibitor,fourth generation
+ SMO inhibitor
Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05150691
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (
DB-1303-O-1001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
+ SMO inhibitor
HER2-positive solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12618001351202
Curative
Not Applicable
Not yet recruiting
A prospective case series evaluating neo-adjuvant use of Vismodegib in patients with periocular basal cell carcinoma to evaluate reduction in clinical and surgical tumour margins
SMO inhibitor,first generation
Cancer
Cutaneous basal cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Not yet recruiting (1)
Recruitment Country and State
QLD (5)
NSW (4)
SA (3)
VIC (3)
WA (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (4)
Trial Type
Advanced (5)
Curative (1)
Cancer Therapy Class
SMO
100%
PD-1/PD-L1
33%
ERBB3
17%
PD-L1
17%
VEGFA
17%
FR-alpha
17%
PD-1
17%
VEGF
17%
AR
17%
B7H3
17%
CYP17A1
17%
androgen axis
17%
ALK
17%
ROS1
17%
ERBB2
17%
Facility
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
5000 - Adelaide - Cancer Research SA (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2109 - North Ryde - Macquarie University Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4215 - Southport - Tasman Oncology (1)
6009 - Nedlands - One Clinical Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3168 - Clayton - Monash Medical Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Cervical cancer
Colorectal cancer
Gastrointestinal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Upper gastrointestinal cancer
Viral-related cancer
Colorectal adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Oesophageal cancer
Uveal melanoma
Breast adenocarcinoma
Endometrial cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Triple-negative breast cancer
HER2-positive solid tumour
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
Skin cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy